Global and regional cardiac function in lifelong endurance athletes with and without myocardial fibrosis. by Eijsvogels, TMH et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=tejs20
Download by: [Radboud Universiteit Nijmegen] Date: 14 September 2017, At: 23:38
European Journal of Sport Science
ISSN: 1746-1391 (Print) 1536-7290 (Online) Journal homepage: http://www.tandfonline.com/loi/tejs20
Global and regional cardiac function in lifelong
endurance athletes with and without myocardial
fibrosis
Thijs M. H. Eijsvogels, David L. Oxborough, Rory O’Hanlon, Sanjay Sharma,
Sanjay Prasad, Greg Whyte, Keith P. George & Mathew G. Wilson
To cite this article: Thijs M. H. Eijsvogels, David L. Oxborough, Rory O’Hanlon, Sanjay Sharma,
Sanjay Prasad, Greg Whyte, Keith P. George & Mathew G. Wilson (2017): Global and regional
cardiac function in lifelong endurance athletes with and without myocardial fibrosis, European
Journal of Sport Science, DOI: 10.1080/17461391.2017.1373864
To link to this article:  http://dx.doi.org/10.1080/17461391.2017.1373864
© 2017 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group
Published online: 14 Sep 2017.
Submit your article to this journal 
View related articles 
View Crossmark data
ORIGINAL ARTICLE
Global and regional cardiac function in lifelong endurance athletes with
and without myocardial fibrosis
THIJS M. H. EIJSVOGELS1,2, DAVID L. OXBOROUGH1, RORY O’HANLON3,
SANJAY SHARMA4, SANJAY PRASAD5, GREG WHYTE1, KEITH P. GEORGE1, &
MATHEW G. WILSON6
1Research Institute for Sports and Exercise Sciences, Liverpool John Moores University, Liverpool, UK; 2Department of
Physiology, Radboud University Medical Center, Nijmegen, Netherlands; 3St. Vincent’s University Hospital and The
Blackrock Clinic, Dublin, Ireland; 4Department of Heart Muscle Disorders and Sports Cardiology, St. Georges Hospital,
London, UK; 5Department of Cardiac Magnetic Resonance Imaging, Royal Brompton and Harefield National Health Service
Trust, London, UK & 6ASPETAR, Qatar Orthopaedic and Sports Medicine Hospital, Doha, Qatar
Abstract
The aim of the present study was to compare cardiac structure as well as global and regional cardiac function in athletes with
and without myocardial fibrosis (MF). Cardiac magnetic resonance imaging with late gadolinium enhancement was used to
detect MF and global cardiac structure in nine lifelong veteran endurance athletes (58 ± 5 years, 43 ± 5 years of training).
Transthoracic echocardiography using tissue-Doppler and myocardial strain imaging assessed global and regional (18
segments) longitudinal left ventricular function. MF was present in four athletes (range 1–8 g) and not present in five
athletes. MF was located near the insertion points of the right ventricular free wall on the left ventricle in three athletes
and in the epicardial lateral wall in one athlete. Athletes with MF demonstrated a larger end diastolic volume (205 ± 24 vs
173 ± 18 ml) and posterior wall thickness (11 ± 1 vs 9 ± 1 mm) compared to those without MF. The presence of MF did
not mediate global tissue velocities or global longitudinal strain and strain rate; however, regional analysis of longitudinal
strain demonstrated reduced function in some fibrotic regions. Furthermore, base to apex gradient was affected in three
out of four athletes with MF. Lifelong veteran endurance athletes with MF demonstrate larger cardiac dimensions and
normal global cardiac function. Fibrotic areas may demonstrate some co-localised regional cardiac dysfunction, evidenced
by an affected cardiac strain and base to apex gradient. These data emphasize the heterogeneous phenotype of MF in athletes.
Keywords: Exercise, cardiac remodelling, echocardiography, late gadolinium enhancement
Abbreviations
A late flow velocity
A′ late diastolic myocardial velocities
BMI body mass index
CMR cardiac magnetic resonance imaging
ε myocardial strain
E early flow velocity
E′ early diastolic myocardial velocity
LGE late gadolinium enhancement
LV left ventricular
MF myocardial fibrosis
RV right ventricular
S′ systolic myocardial velocity
SRA late diastolic strain rate
SRE early diastolic strain rate
SRS systolic strain rate
Introduction
Habitual physical activity is known to improve cardi-
ovascular health and reduces the risk for cardiovascu-
lar morbidity and mortality in a dose-dependent
fashion (Eijsvogels & Thompson, 2015). High
volumes of exercise training typically lead to cardiac
remodelling which is characterized by biventricular
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enlargement, increased left ventricular (LV) wall
thickness and left atrial enlargement (Utomi et al.,
2013). These exercise-induced adaptations are gen-
erally considered benign, but emerging evidence
suggests that cardiac mal-adaptations may occur in
a minority of endurance athletes after chronic exer-
cise training (Eijsvogels, Fernandez, & Thompson,
2016).
Myocardial fibrosis (MF), or scarring of the heart
tissue, is commonly found after myocardial ischemia,
inflammation or hypertensive overload as part of
pathophysiological cardiac remodelling processes
(Hill & Olson, 2008) and is a strong predictor for
major adverse cardiac events (Kwong et al., 2008).
MF has been reported in 7.9–19.8% of the general
population using cardiac magnetic resonance
(CMR) imaging with late gadolinium enhancement
(LGE) (Barbier, Bjerner, Johansson, Lind, & Ahl-
strom, 2006; Schelbert et al., 2012; Turkbey et al.,
2015). Somewhat counterintuitively, a high preva-
lence of MF has also been observed in veteran endur-
ance athletes, with evidence of LGE in 12–50% of
some athletic populations (Breuckmann et al.,
2009; La Gerche et al., 2012; Wilson et al., 2011).
A recent study confirmed the higher prevalence of
MF in male veteran athletes compared to age-
matched controls (Merghani et al., 2017). The occur-
rence and magnitude of MF have been positively
related to the volume of the lifelong exercise training
(Breuckmann et al., 2009; La Gerche et al., 2012; van
de Schoor et al., 2016; Wilson et al., 2011). In
cardiac patients, MF is associated with an increased
risk of arrhythmias (Kramer et al., 2014), an increase
in myocardial stiffness and a reduction of cardiac
function (Sugihara et al., 1988). The impact of MF
in athletes upon global and co-localised regional
cardiac function remains to be fully examined.
The aim of this study was to compare cardiac struc-
ture as well as global and regional cardiac function in
athletes with and without MF. For this purpose, we
performed CMR imaging and transthoracic echocar-
diography imaging utilising global and regional
assessment of myocardial strain (ε) in a small
cohort of lifelong veteran endurance athletes
(Wilson et al., 2011). We hypothesize that athletes
with MF will present with similar cardiac structure
and global cardiac function as athletes without MF.
We speculate that regional dysfunction may be co-
localised with MF in some athletes.
Methods
Data from the present study represent a sub-analyses
of previous work from our group (Wilson et al.,
2011). Cardiac structure and function measurements
were performed in a subsample (n = 9 out of n = 12)
of veteran athletes (6 runners, 2 rowers and 1 triath-
lete) that performed lifelong exercise training on a
high intensity/frequency. One participant was a
former elite athlete, all other athletes were highly
trained amateurs. As previously described (Wilson
et al., 2011), participants were recruited via an adver-
tisement placed in the United Kingdom’s 100 Mara-
thon running club newsletter and the British Olympic
Association’s “Olympian” magazine. Given the
inclusion criteria, we anticipated on a small sample
size in this case series manuscript. Athletes were 58
± 5 years old, had a BMI of 24.1 ± 2.5 kg/m2,
reported 43 ± 5 years of continuous exercise training
and were free from (known) cardiovascular diseases
and diabetes upon inclusion. Participants were
asked to limit their volume of exercise training (i.e.,
<20 miles/week or an equivalent exercise load) in
the week prior to study participation, with no training
in the 48 hours prior to any scheduled measurements.
The study received ethical approval from the Royal
Brompton Hospital and the National Heart and
Lung Institute research ethics committee. All partici-
pants provided written informed consent and the
study was performed in line with the Declaration of
Helsinki.
A standard cardiac volume, wall dimension, func-
tion and LGE sequence was performed on a dedi-
cated scanner (Siemens Avanto 1.5-T, Erlangen,
Germany), with full myocardial coverage. Left and
right ventricular volumes, mass and function were
quantified using customized analysis software
(CMRtools, Cardiovascular Imaging Solutions,
London, UK) by a blinded, single experienced inves-
tigator. Papillary muscles were included in the mass
and excluded from the volume.
Identification of MF was performed as previously
described (Wilson et al., 2011). In brief, imaging
for LGE was performed 5–10 min after gadolinium
contrast injection in identical short-axis planes to
cine images using a breath-hold inversion-recovery
(fast low-angle shot) gradient echo sequence. Inver-
sion times were optimized to null normal myocar-
dium. In all participants, LGE imaging was
repeated for each short-axis image in two separate
phase-encoding directions to exclude artefact. LGE
images were analyzed quantitatively by two indepen-
dent readers using customized software (MRI-
MASS, Medis, Leiden, the Netherlands).
All echocardiographic images were acquired using
a commercially available ultrasound system (Vivid Q,
GE Medical, Horten, Norway) with a 1.5–4 MHz
phased array transducer. Images were obtained by
an experienced sonographer with the participant in
the left lateral decubitus position. Images were
recorded to DVD in raw DICOM format and data
2 T. M. H. Eijsvogels et al.
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were analysed offline by a single experienced
researcher using commercially available software
(EchoPac version 7, GE Medical, Horten, Norway).
Standard pulsed wave Doppler of transmitral flow
was used to obtain early (E) and late (A) flow vel-
ocities and their ratio was calculated (E/A). In
addition, a 4 mm pulsed wave tissue-Doppler
sample was applied to the septal and lateral annuli
in order to provide systolic (S′), early diastolic (E′)
and late diastolic myocardial velocities (A′). An
average of the two sites was calculated and E/E′ was
derived as a marker of LV filling pressure.
For the assessment of longitudinal LV strain (ε),
2D speckle tracking images of the left ventricle were
acquired from apical four, two and three chamber
orientations and were optimised in order to maximise
the signal to noise ratio and endocardial delineation.
Frame rates were ≥40 fps whilst a single focal zone
was positioned at mid-chamber to reduce the
impact of beam divergence (Oxborough, George, &
Birch, 2012). Offline analysis involved a region of
interest being placed transmurally in all three apical
orientations. This provided ε from 18 myocardial
segments including basal, mid and apical infero-
septum, lateral wall, inferior wall, anterior wall, pos-
terior wall and antero-septum. Regional peak longi-
tudinal ε and systolic, early diastolic and late
diastolic strain rates were obtained for each segment
and an overall (global) ε value was calculated as an
average of all 18 segments.
To assess the impact of MF on regional ε data, we
combined CMR imaging and echocardiography data.
The location of MF from CMR images was matched
to ε data from 18 myocardial segments on an individ-
ual basis. The ε data in the athletes with MF were
compared with non-fibrotic segments within the
athlete and with the average ε data in the same seg-
ments in all athletes without MF. The difference in
ε (Δε) between athletes without and withMF was cal-
culated. Base to apex gradient (%) was calculated in
the MF-affected cardiac wall using the four
chamber view. Time to peak stain (milliseconds)
was calculated similarly to local ε data.
Data are reported as mean ± standard deviation or
percentage unless specified otherwise. We did not
perform statistical analyses due to the low sample
size of our study population. Alternatively, descrip-
tive statistics were provided to compare cardiac struc-
ture and function between veteran athletes with and
without MF.
Results
There was no evidence of MF in five athletes. LGE,
and thus MF, was present in four athletes,
representing 1–8 gram (g) of the myocardium. The
LGE pattern was non-specific in three athletes, with
MF located near the insertion points of the right ven-
tricular free wall on the left ventricle. One athlete
demonstrated MF in the epicardial lateral wall, con-
sistent with a previous episode of myocarditis. Age,
anthropometric characteristics, blood pressure,
heart rate and training history did not differ
between athletes with MF (n = 4) and without MF
(n = 5) (Table I).
Athletes with MF demonstrated a larger left ventri-
cle end diastolic volume (205 ± 24 vs 173 ± 18 ml)
compared to athletes without MF. LV end systolic
volume was comparable between both groups
(Table II). Right ventricular end-diastolic and end
systolic volumes were comparable between athletes
with and without MF. Posterior wall thickness was
significantly larger in MF athletes (11 ± 1 mm) com-
pared to peers without MF (9 ± 1 mm).
Global peak diastolic Doppler flow and regional
tissue-Doppler velocities are summarized in Table
II. E, A, E/A ratio as well as E′ and A′ myocardial vel-
ocities and the E/E′ ratio were comparable between
groups. Also, average S′ did not differ between ath-
letes with and without MF (9 ± 2 vs 9 ± 2 cm/s).
Global LV longitudinal ε and strain rate data are pre-
sented in Table II and did not differ between athletes
with and without MF.
Segmental analyses of longitudinal ε, base to apex
gradient and time to peak strain in fibrotic versus
non-fibrotic regions were summarized in Table III.
Case #1 had improved ε values compared to his
own non-fibrotic segments (21.5% ± 4.9%) but also
compared to athletes without MF across all three seg-
ments (Δε range: 4.7–7.5%). In contrast, Case #2
Table I. Subject characteristics of the veteran athletes with and
without myocardial fibrosis.
Without fibrosis
(N= 5)
With fibrosis
(N= 4)
Age (yrs) 59 ± 2 57 ± 8
Height (cm) 180 ± 7 179 ± 6
Weight (kg) 80 ± 14 75 ± 7
BMI (kg/m2) 24.6 ± 3.1 23.5 ± 1.7
BSA (m2) 2.0 ± 0.2 1.9 ± 0.1
SBP (mmHg) 123 ± 4 120 ± 9
DBP (mmHg) 78 ± 9 75 ± 6
HR (bpm) 58 ± 8 50 ± 6
Exercise training (yrs) 44 ± 2 42 ± 8
Type of athlete
Runner (n) 4 2
Rower (n) 1 1
Triathlete (n) 0 1
Notes: BMI: body mass index; BSA: body surface area; SBP:
systolic blood pressure; DBP: diastolic blood pressure; HR: heart
rate.
Cardiac function in athletes with myocardial fibrosis 3
D
ow
nl
oa
de
d 
by
 [R
ad
bo
ud
 U
niv
ers
ite
it N
ijm
eg
en
] a
t 2
3:3
8 1
4 S
ep
tem
be
r 2
01
7 
demonstrated similar ε in fibrotic compared to non-
fibrotic segments, whereas local ε was comparable
in the mid septum segment (Δε: 0.9%) but reduced
in the apical septum segment (Δε: −7.7%) compared
to athletes without MF. Case #3 demonstrated lower
ε in fibrotic versus non-fibrotic segments, whereas
local ε in MF segments was improved (Δεmid anterior
septum: 2.2%) similar (Δεmid septum: −0.9%) and
lower (Δεbasal septum: −2.0%, Δεbasal anterior septum:
−3.4%) compared to athletes without MF. Case #4
demonstrated comparable (mid septum) and
increased (apical septum) ε in fibrotic versus non-
fibrotic segments, whereas local ε was lower (Δεmid
septum: −4.2% and Δεapical septum: −7.0%) compared
to values in athletes without MF (Table III). Base
to apex gradient was similar for case #1, lower for
case #2 and #4 and higher for case #3. No differ-
ences in time to peak strain were observed due to
large variability across segments.
Discussion
This case series is the first to describe the cardiac
structure as well as LV global and regional function
in athletes with and without MF. We found that life-
long veteran athletes withMF had a larger LV dimen-
sion than peers without MF. The presence of MF,
however, did not impact upon global systolic or dias-
tolic function, including global longitudinal ε and
strain rate. Co-localisation of MF and regional ε
data revealed that some, but not all, athletes with
MF-demonstrated attenuated regional cardiac func-
tion. Furthermore, base to apex gradient was affected
in three out of four athletes with MF. Findings from
this case series indicate that the impact of anMF phe-
notype on cardiac structure and function is highly
variable across athletes and may result in co-localized
cardiac dysfunction.
CMR imaging revealed that athletes with MF
demonstrated larger cardiac dimensions (LV end
diastolic volume and posterior wall thickness) com-
pared to athletes without MF. These findings
suggest that the hearts of athletes with MF are
bigger than athletes without MF. Exercise training
is a known stimulus for cardiac remodelling, and
higher volumes of exercise result in greater remodel-
ling.(Pluim, Zwinderman, van der Laarse, & van der
Wall, 2000; Utomi et al., 2013) The training history
of the veteran athletes with and without MFwas com-
parable (42 ± 8 vs 44 ± 2 yrs) and is, therefore, unli-
kely to explain this finding. Alternatively, athletes
with MF may be more prone to cardiac remodelling.
Several cross sectional (George et al., 2011; Pelliccia,
Maron, Spataro, Proschan, & Spirito, 1991) and
longitudinal studies (Arbab-Zadeh et al., 2014;
Table II. Cardiac indices, diastolic function, LV global strain and
strain rate characteristics of athletes with and without myocardial
fibrosis.
Without fibrosis
(N= 5)
With fibrosis
(N= 4)
Cardiac indices (MRI)
LVEDV (ml) 173 ± 18 205 ± 24
LVESV (ml) 61 ± 17 74 ± 13
LVSV (ml) 112 ± 6 131 ± 22
LVEF (%) 65 ± 6 64 ± 4
LV length (mm) 86 ± 6 91 ± 7
LV mass (g) 140 ± 16 154 ± 14
RVEDV (ml) 177 ± 16 198 ± 32
RVESV (ml) 64 ± 14 69 ± 20
RVSV (ml) 114 ± 7 129 ± 18
RVEF (%) 64 ± 5 66 ± 6
IVSd (mm) 10 ± 1 12 ± 2
PWd (mm) 9 ± 1 11 ± 1
Diastolic function (Echo)
E (cm/s) 65 ± 6 62 ± 10
A (cm/s) 60 ± 11 58 ± 5
E/A ratio 1.1 ± 0.3 1.1 ± 0.2
Septal E (cm/s) 10 ± 2 10 ± 2
A (cm/s) 11 ± 2 11 ± 1
Lateral E (cm/s) 11 ± 1 14 ± 3
A (cm/s) 11 ± 2 11 ± 1
Average E (cm/s) 11 ± 1 12 ± 2
A (cm/s) 11 ± 2 11 ± 1
E/E 6 ± 1 5 ± 2
Longitudinal strain (Echo)
2CH (%) −22.7 ± 1.9 −21.9 ± 4.4
4CH (%) −21.7 ± 2.9 −22.6 ± 3.5
APLAX (%) −20.7 ± 4.5 −21.3 ± 5.2
Overall (%) −21.7 ± 1.8 −22.0 ± 4.3
Longitudinal strain rate (Echo)
2CH S (l/s) −1.06 ± 0.16 −0.95 ± 0.21
E (l/s) 0.85 ± 0.11 0.93 ± 0.16
A (l/s) 0.75 ± 0.15 0.56 ± 0.13
4CH S (l/s) −1.05 ± 0.18 −1.03 ± 0.20
E (l/s) 0.96 ± 0.22 1.02 ± 0.30
A (l/s) 0.66 ± 0.25 0.60 ± 0.21
APLAX S (l/s) −0.95 ± 0.16 −0.94 ± 0.19
E (l/s) 0.88 ± 0.28 0.91 ± 0.22
A (l/s) 0.57 ± 0.20 0.67 ± 0.16
Overall S (l/s) −1.02 ± 0.11 −0.97 ± 0.19
E (l/s) 0.90 ± 0.15 0.95 ± 0.20
A (l/s) 0.66 ± 0.17 0.61 ± 0.16
Notes: LVEDV: left ventricular end diastolic volume; LVESV: left
ventricular end systolic volume; LVSV: left ventricular stroke
volume; LVEF: left ventricular ejection fraction; LV: left ventricle;
RVEDV: right ventricular end diastolic volume; RVESV: right
ventricular end systolic volume; RVSV: right ventricular stroke
volume; RVEF: right ventricular ejection fraction; IVSd:
intraventricular septum thickness; PWd: Posterior wall thickness;
2CH: apical two chamber view; 4CH: apical four chamber view;
APLAX: apical parasternal long axis view; E: early diastolic filling
(E-wave); A: late diastolic filling (A-wave); E (cm/s): early diastolic
velocity of mitral annulus; A (cm/s): late diastolic velocity of mitral
annulus; S (l/s): systolic strain rate; E (l/s): early diastolic strain rate;
A (l/s): late diastolic strain rate.
4 T. M. H. Eijsvogels et al.
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Weiner et al., 2015) demonstrated that the magni-
tude of exercise-induced cardiac remodelling differs
substantially across athletes. Genetic, epigenetic
and environmental factors may contribute to the
inter-individual differences of remodelling (Eijsvo-
gels & Thompson, 2017). Hence, athletes with MF
may be predisposed to greater levels of cardiac adap-
tation, potentially leading to a shift of the physiologi-
cal to pathological remodelling continuum and
subsequently to the development of MF.
No differences in global diastolic function and
indices of global longitudinal ε and strain rate were
found between athletes with and without MF.
These observations contradict findings in cardiovas-
cular patients with MF. For example, patients with
congenital aortic stenosis (Dusenbery et al., 2015),
Fabry disease (Kramer et al., 2013) and hypertrophic
cardiomyopathy (Saito et al., 2012) that had LGE
demonstrated significant reductions in cardiac func-
tion compared to patients without LGE and healthy
controls. Furthermore, ε patterns were related to the
magnitude of MF (Kramer et al., 2013; Saito et al.,
2012), indicating that higher volumes of MF are
associated with further attenuation of global longitudi-
nal ε. The low volumes of LGE in our cases may
contribute to the lack of impact of MF on global
indices of cardiac function in veteran athletes with
MF. Alternatively, the physically active lifestyle of
our study population may ameliorate the detrimental
effects of MF on strain and strain rate.
Data from regional/segmental analyses (Table III)
revealed a more variable and complex outcome com-
pared to global measures of cardiac function. An atte-
nuated LV longitudinal ε in fibrotic versus non-
fibrotic segments was observed within an MF
athlete (n = 1) and also compared to the control
group (n= 3). Furthermore, a reduced base to apex
gradient was observed in athletes with MF in the
apical segment (case #2 and #4), whereas a larger
gradient was found in an athlete with MF in the
basal segment (case #3). These observations
suggest that presence of subtle MF near the insertion
point may impact cardiac function at a regional or
local level. Interestingly, the case (#1) with the
largest volume of MF (8 g) actually demonstrated a
superior ε compared to the reference group of five
athletes without MF. A different aetiology for the
development of MF in case #1 versus cases #2, #3
and #4 may explain this observation. Case 1 presents
an MF pattern which is consistent with a previous
Table III. A comparison of regional data between fibrotic and non-fibrotic segments withinMF athletes and also in comparison with the same
wall segment in athletes without MF.
Athlete with MF Athletes without MF (n = 5)
Longitudinal
strain (%)
Base to apex
gradient (%)
Time to peak
strain (ms)
Longitudinal
strain (%)
Base to apex
gradient (%)
Time to peak
strain (ms)
Case #1: MF at epicardial lateral
wall (8 g)
−0.1 −1.1 ± 6.3
4CH – Apical lateral −26.5 405 −21.8 ± 2.4 376 ± 23
4CH – Mid lateral −24.2 405 −16.7 ± 6.1 405 ± 80
4CH – Basal lateral −26.4 473 −19.5 ± 4.9 403 ± 67
4CH – Non-fibrotic segments −21.5 ± 4.9 427 ± 70 −22.8 ± 5.2 383 ± 46
Case #2: MF at inferior insertion
point mid and apical (3 g)
−3.8 −10.4 ± 5.9
4CH – Mid septum −22.5 351 −21.6 ± 1.7 377 ± 44
4CH – Apical septum −20.9 351 −28.6 ± 3.7 405 ± 51
4CH – Non-fibrotic segments −20.8 ± 5.5 428 ± 98 −19.1 ± 4.4 388 ± 56
Case #3: MF at basal and mid
insertion point (3 g)
−14.4 −10.4 ± 5.9
4CH – Basal septum −16.2 358 −18.2 ± 2.8 369 ± 43
4CH – Mid septum −20.7 358 −21.6 ± 1.7 377 ± 44
4CH – Non-fibrotic segments −29.1 ± 3.5 387 ± 19.5 −21.7 ± 6.1 397 ± 56
APLAX – Mid anterior septum −26.5 426 −24.3 ± 3.9 430 ± 35
APLAX – Basal anterior septum −18.5 497 −21.9 ± 6.7 419 ± 51
APLAX –Non-fibrotic segments −28.2 ± 4.0 382 ± 34 −19.2 ± 6.0 376 ± 51
Case #4: MF at insertion point
inferior mid/apical (1 g)
−5.4 −10.4 ± 5.9
4CH – Mid septum −17.4 326 −21.6 ± 1.7 377 ± 44
4CH – Apical septum −21.6 407 −28.6 ± 3.7 405 ± 51
4CH – Non-fibrotic segments −18.4 ± 1.7 326 ± 57 −19.1 ± 4.4 388 ± 56
Notes: MF: myocardial fibrosis; 4CH: apical four chamber view; APLAX: apical parasternal long axis view.
Cardiac function in athletes with myocardial fibrosis 5
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episode of myocarditis whereas the other cases had a
non-specific LGE pattern. Myocarditis is known to
induce MF, but these pathological remodelling pro-
cesses are mainly restricted to the epicardial wall
(Pressler et al., 2011). Hence, the non-transmural
nature of MF in case #1 may have been insufficient
to impact regional ε patterns.
Findings from the present study may have clinical
implications. Firstly, the observation that athletes
with MF have bigger hearts than their non-fibrotic
peers is of interest but requires confirmation in a
larger population of athletes with and without MF.
Furthermore, CMR imaging could be a potential
valuable additional technique for risk stratification
in lifelong athletes with cardiac dimensions near the
upper limit of physiological remodelling. Secondly,
our data demonstrates that the functional impact of
MF in athletes is heterogeneous, with some athletes
demonstrating a reduction in local ε patterns and
base to apex gradient, whereas others demonstrate
preserved cardiac function. Whether the observed
regional dysfunction may contribute to adverse cardi-
ovascular outcomes is unknown. A previous study
demonstrated that German marathoners with MF
had a higher incidence of revascularisation therapy
(25% versus 1%, p < .001) and MF was associated
with higher coronary artery calcification scores (192
versus 26, p< .005) compared to marathoners
without MF (Breuckmann et al., 2009; Mohlenkamp
et al., 2008). Therefore, future large sample-sized
studies that explore the link between MF-induced
regional dysfunction and long-term major adverse
cardiovascular events are warranted.
An important limitation of this study is the limited
number of athletes that were measured. Nevertheless,
the prevalence of MF in athletes is low, and only 30
cases were identified worldwide (van de Schoor
et al., 2016). This means that it is extremely hard to
recruit a larger sample size. Further work utilising
T1 mapping sequences to image interstitial fibrosis
may prove promising in athletic heart assessment
(Gormeli et al., 2016).
Conclusions
In conclusion, findings from the present case series
suggest that the presence of MF may be associated
with larger cardiac dimensions and regional cardiac
dysfunction in lifelong veteran endurance athletes.
It is important to emphasize that these characteristics
are presented by some, but not all, athletes with
MF. Findings from the present study should, there-
fore, be considered as hypothesis generating and
should lead to novel studies in this field of exercise
physiology and sports cardiology.
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